tralokinumab-ldrm (Adbry, Adtralza)

Indications

• treatment of atopic dermatitis
  • may be used with or without topical glucocorticoids

Dosage

• initial dose of 600 mg SQ (4 150 mg injections)
• follow with 300 mg (2 150 mg injections) SQ every other week.
• 300 mg every 4 weeks may be considered for patients below 100 kg who achieve clear or almost clear skin after 16 weeks of treatment

* 1 mL 50 mg/mL prefilled syringe

* 2 mL tralokinumab-ldrm 150 mg/mL auto-injector for subcutaneous injection

Adverse effects

• hypersensitivity reactions
• keratitis & conjunctivitis
• eosinophilia & helminth infections

• drug adverse effects of pharmaceutical monoclonal antibodies

Mechanism of action

• human IgG4 monoclonal antibody that specifically binds to human interleukin-13 (IL-13)

More general terms

• pharmaceutical monoclonal antibody
• dermatologic agent